Johnson & Johnson Innovation Establishes Network of Partnering Offices in UK Life Sciences Clusters

  Johnson & Johnson Innovation Establishes Network of Partnering Offices in UK
  Life Sciences Clusters

Business Wire

LONDON -- December 9, 2013

Johnson & Johnson Innovation, London, today announces the formation of a
network of partnering offices across UK life science clusters. The offices
function as extensions of its London Innovation Centre to work with academics
and entrepreneurs throughout the UK to identify early stage innovation and
support the translation of research into new products for patients.

While the London Innovation Centre continues to be the primary hub for
interactions with the academic and entrepreneurial community in the greater
London area, these new partnering offices are part of a broader strategy to
interact more directly with life science “hotspots” throughout the UK and
Europe.

Johnson & Johnson Innovation is establishing partnering offices in the
following locations that will function as a base for interactions throughout
the regions:

  *Babraham Research Campus for the wider Cambridge area
  *University of Oxford Old Road Campus for the wider Oxford area
  *The University of Manchester Innovation Centre (UMIC) for the North and
    Midlands
  *Edinburgh BioQuarter for Scotland and Northern Ireland
  *Life Sciences Hub Wales in Cardiff for Wales and the South West

Representatives from the Johnson & Johnson Innovation Centre in London will
establish a regular presence in each of the partnering offices that are
expected to be fully operational in early 2014.

"Establishing these partnering offices reflects our commitment to
collaborative innovation and our belief that being close to the source of
innovation drives our ability to create strong networks of people who can
combine ideas, resources and technologies in a new way to tackle urgent unmet
medical needs,” commented Patrick Verheyen, head of the Johnson & Johnson
Innovation Centre, London.

“Opening these new partnering offices extends the approach we piloted with
Stevenage Bioscience Catalyst (SBC) earlier this year,” commented Dr. Kurt
Hertogs, Incubator Strategy Leader for the Johnson & Johnson Innovation,
London. “Our continuing experience with SBC confirms this model as an
effective way for our scientific teams to interact with innovators and
entrepreneurs, and advance promising healthcare solutions. Given the number
and diversity of research campuses, incubators, and life science parks
throughout the UK and Europe, we believe the establishing of these regional
partnering offices will enable us to reach out and more effectively
collaborate with innovators across the UK and Europe.”

About Johnson & Johnson Innovation

The London Innovation Centre is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Limited. Johnson & Johnson Innovation
focuses on accelerating early innovation and enhancing opportunities for
collaboration and investment across Johnson & Johnson’s global healthcare
businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs
and emerging companies focused on early stage opportunities a one-stop access
to science and technology experts who can facilitate collaborations across the
pharmaceutical, medical device and diagnostics and consumer companies of
Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making
capabilities with the flexibility to adapt deal structures to match
early-stage opportunities and establish novel collaborations that speed
development of innovations to solve unmet needs in patients. For more
information please visit: www.jnjinnovation.com.

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson & Johnson
Innovation, Johnson & Johnson Finance Limited and/or Johnson & Johnson. Risks
and uncertainties include, but are not limited to, general industry conditions
and competition; economic factors, such as interest rate and currency exchange
rate fluctuations; technological advances, new products and patents attained
by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; changes in behavior and
spending patterns or financial distress of purchasers of health care products
and services; changes to governmental laws and regulations and domestic and
foreign health care reforms; trends toward health care cost containment; and
increased scrutiny of the health care industry by government agencies. A
further list and description of these risks, uncertainties and other factors
can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K
for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well
as subsequent filings, are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. None of Johnson & Johnson Innovation, Johnson
& Johnson Finance Limited or Johnson & Johnson undertake to update any
forward-looking statements as a result of new information or future events or
developments.)

                                     ###

Contact:

Johnson & Johnson
Ellen Rose
+44 (0)7767 267493
erose89@its.jnj.com
or
Seema Kumar
908-405-1144
Skumar10@its.jnj.com